Rationale and study design for a randomized clinical trial of HOPE-Genomics, a web-based intervention to improve cancer patients' understanding of genomic testing results
Contemporary Clinical Trials · 2026-08 · 167 · 108358
DOI: 10.1016/j.cct.2026.108358 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Contemporary Clinical Trials, 2026-08. Verfasst von Ilana B Solomon und 24 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology and Therapeutics Research, City of Hope National Medical Center, Duarte, CA, United States of America; Center for Prec…. Hauptthemen laut MEDLINE: Neoplasms, Genetic Testing, Internet-Based Intervention, Patient Education as Topic. Die Arbeit nennt 49 Literaturangaben. Gefördert von: American Cancer Society Inc, Foundation for the National Institutes of Health, National Institutes of Health.
Themen: Onkologische Pflege
Abstract (Originalsprache)
BACKGROUND: Genomic testing is rapidly being incorporated into cancer care. The results of somatic (tumor) and germline (normal) DNA testing can have implications for treatment, management of future cancer risk, and the health of family members. Despite these benefits, many patients fail to understand genomic concepts and their testing results. To address these knowledge gaps, we developed Helping Oncology Patients Explore (HOPE) Genomics. HOPE-Genomics is an interactive, web-based tool that 1) educates patients about genomics, 2) enables direct-to-patient return-of-results (ROR), and 3) facilitates sharing of genomic results within families. Herein we describe an NIH-funded randomized clinical trial (RCT) to test the intervention efficacy. METHODS: We will conduct a prospective, three-arm, RCT of HOPE-Genomics among cancer patients (n = 435) who have received somatic, germline or paired sequencing. Patients will be randomized into one of three arms: (1) Control (i.e., Usual Care), (2) return of results (ROR) through HOPE-Genomics and (3) pre-test genetic education and ROR through HOPE-Genomics. We will survey patients at 5 timepoints over 12 months. The primary study outcome will be patients' genetic testing recall at 10-day post-disclosure. Secondary outcome will be receipt of genomically-informed, guideline concordant care. Exploratory outcomes will include recall of genetic testing at 3-month post-disclosure, and general and cancer genetic knowledge. CONCLUSION: Our hypothesis is that the use of HOPE-Genomics will result in higher rates of recalling genetic testing, better understanding of general genomic knowledge and higher uptake of evidence-based genetically guided care. If effective, HOPE-Genomics could serve as a scalable model for genomics education and care delivery. TRIAL REGISTRATION: ClinicalTrials.gov identifier NCT04905082.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Medical Oncology and Therapeutics Research, City of Hope National Medical Center, Duarte, CA, United States of America; Center for Precision Medicine, City of Hope National Medical Center, Duarte, CA, Unit…
- Stem Cell Transplant, City of Hope National Medical Center, Duarte, CA, United States of America.
- Charles R. Drew University of Medicine and Science, Los Angeles, CA, United States of America.
- University of Arizona, College of Medicine, Tucson, AZ, United States of America.
- California Northstate University, College of Medicine, Elk Grove, CA, United States of America.
- Department of Medical Oncology and Therapeutics Research, City of Hope National Medical Center, Duarte, CA, United States of America.
Förderung
- American Cancer Society Inc
- Foundation for the National Institutes of Health
- National Institutes of Health
Zitieren
APA
Solomon, I. B., Luong, M., Currey, M., Labib, S., Tang, S., Martinez, J., Suarez, C., Qiao, R., Mak, A., Cheung, F., Manookian, R., Xiao, Y., Garcia, M., Seshadri, A., Jinadu, J., Kim, M., Martinez, R., White, P., Martinez, F., …, & Gray, S. W. (2026). Rationale and study design for a randomized clinical trial of HOPE-Genomics, a web-based intervention to improve cancer patients' understanding of genomic testing results. Contemporary Clinical Trials, 167, 108358. https://doi.org/10.1016/j.cct.2026.108358
Vancouver
Solomon IB, Luong M, Currey M, Labib S, Tang S, Martinez J, et al. Rationale and study design for a randomized clinical trial of HOPE-Genomics, a web-based intervention to improve cancer patients' understanding of genomic testing results. Contemporary Clinical Trials. 2026;167:108358. doi:10.1016/j.cct.2026.108358
BibTeX
@article{Solomon2026,
author = {Solomon, Ilana B and Luong, Marilan and Currey, Madeline and Labib, Sarah and Tang, Sarah and Martinez, Justin and Suarez, Cassiel and Qiao, Ran and Mak, Angela and Cheung, Frances and Manookian, Rachelle and Xiao, Yi and Garcia, Michael and Seshadri, Amarnath and Jinadu, Jay and Kim, Minsub and Martinez, Robert and White, Philip and Martinez, Fortino and Rout, Ramesh and Sharifara, Ali and Zhou, Coco and Boyd, Patrick and Davey, Sandra and Gray, Stacy W},
title = {Rationale and study design for a randomized clinical trial of HOPE-Genomics, a web-based intervention to improve cancer patients' understanding of genomic testing results},
journal = {Contemporary Clinical Trials},
year = {2026},
volume = {167},
pages = {108358},
doi = {10.1016/j.cct.2026.108358}
}
EUVIMED